Sacrosidase - Biologic Drug Details

Summary for sacrosidase

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for sacrosidase

Recent Clinical Trials for sacrosidase

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
QOL Medical, LLC	Phase 2
QOL Medical, LLC	Phase 4

See all sacrosidase clinical trials

Pharmacology for sacrosidase

Established Pharmacologic Class

Sucrose-specific Enzyme

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for sacrosidase Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for sacrosidase Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for sacrosidase Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Sacrosidase

Last updated: February 23, 2026

What is the current market landscape for sacrosidase?

Sacrosidase, marketed as Sucraid, is a recombinant enzyme used to treat congenital sucrose intolerance, a rare genetic disorder where patients cannot digest sucrose. The drug’s market is niche, with an estimated prevalence of 1 in 100,000 newborns. It primarily targets pediatric patients in developed countries, with sporadic use in Europe and limited penetration in emerging markets.

The global demand remains modest, given the disorder's rarity. The U.S. Food and Drug Administration (FDA) approved sacrosidase in 2001, with the European Medicines Agency (EMA) granting conditional approval in 2004. It remains an orphan drug, qualifying for market exclusivity.

How does sacrosidase's competitive landscape shape?

Sacrosidase fares against alternative management strategies such as dietary modification and enzyme replacement therapies. No direct competitor with identical mechanisms exists, but the broader enzyme replacement therapy (ERT) market overlaps with other metabolic enzyme deficiencies—such as Fabry disease and Gaucher's disease—where companies like Advanced Therapeutics and Akari therapeutics operate.

Manufacturers hold market exclusivity until patents expire, typically 7-12 years post-approval. The original patent for sacrosidase was filed in 1993 and expired in 2008, opening potential generic or biosimilar competition, although no biosimilars are on the market as of 2023.

What are the key factors influencing market growth?

There are three main factors:

1. Prevalence and Diagnosis Rates: Accurate diagnosis influences market size. Advances in genetic testing have increased detection, but underdiagnosis persists, especially in underserved regions.

2. Regulatory Environment: Orphan drug designations provide incentives like tax credits and market exclusivity, encouraging continued R&D. Changes in orphan drug policies could expand or limit market opportunities.

3. Pricing and Reimbursement: Sacrosidase's high treatment cost (~$20,000 annually per patient) depends on insurance reimbursement. Variability across regions limits access and adoption.

What are the revenue projections for sacrosidase?

Given the low prevalence, the estimated U.S. market size is approximately 300-500 patients. Pricing approximately $20,000 per year yields potential annual revenue of $6-$10 million in the U.S. alone. Global reach remains limited; Europe accounts for roughly 50-60 patients, with similar pricing strategies.

Growth depends on increased diagnosis, expanded indication, and potential pipeline developments. No active clinical trials are underway for new formulations or indications.

How does the future outlook appear for sacrosidase?

Market growth is constrained by the rare disease status, small patient population, and lack of competition. However, potential expansion exists via:

• Expanded indications: Off-label use or research into related sucrose metabolism disorders.
• Improved diagnostics: New genetic screening programs could identify undiagnosed patients, increasing treatment numbers.
• Policy shifts: U.S. and European governments enhancing orphan drug incentives may preserve or extend exclusivity or facilitate market access.

Financial trajectories for manufacturers depend on sales volume, pricing strategies, and reimbursement policies. The high-cost structure and small patient pool limit upside unless new indications or broader adoption occur.

Key financial considerations

Parameter	Estimate	Notes
Market size (US)	300-500 patients	Based on estimated prevalence
Price per patient	$20,000	Approximate annual treatment cost
Potential revenue	$6-$10 million	US market only
Global market	Same per-patient cost	Limited by diagnosis and awareness

Key Takeaways

• Sacrosidase operates in a niche market with low prevalence.
• The drug's revenue potential remains constrained by the small patient population.
• Market growth hinges on diagnosis improvements and policy incentives.
• No current biosimilar competition exists due to patent expiration delays.
• Expanding indications face scientific and regulatory hurdles.

FAQs

1. Will sacrosidase experience generic competition?
It is unlikely in the near term. No biosimilar has entered the market, partly due to complex manufacturing and regulatory barriers for enzyme biologics.

2. What are primary obstacles to expanding sacrosidase's market?
Limited awareness, diagnostic challenges, high treatment costs, and regulatory hurdles restrict broader adoption.

3. Are there ongoing clinical trials for sacrosidase?
No active clinical trials for new indications or formulations are registered as of 2023.

4. What are the prospects for increasing the use of sacrosidase in emerging markets?
Growth depends on improving diagnosis infrastructure and regulatory pathways, which currently lag behind developed regions.

5. How might policy changes affect sacrosidase’s market?
Enhanced orphan drug incentives and reimbursement support could sustain or mildly expand market access, but significant growth remains unlikely due to disease rarity.

---

References

[1] Food and Drug Administration. (2001). FDA Approval for Sacrosidase.
[2] European Medicines Agency. (2004). EMA Conditional Approval of Sacrosidase.
[3] Orphan Drug Designation, U.S. FDA. (2022).
[4] MarketWatch. (2023). Orphan drug market analysis.
[5] GlobalData. (2022). Enzyme replacement therapy market report.